Innoviva Return on Investment 2012-2026 | INVA
Current and historical return on investment (ROI) values for Innoviva (INVA) over the last 10 years.
| Innoviva ROI - Return on Investment Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | LT Investments & Debt | Return on Investment |
| 2026-03-31 | $0.16B | $1.32B | 12.22% |
| 2025-12-31 | $0.16B | $1.14B | 14.34% |
| 2025-09-30 | $0.17B | $1.02B | 16.43% |
| 2025-06-30 | $0.18B | $0.94B | 18.78% |
| 2025-03-31 | $0.18B | $0.97B | 18.72% |
| 2024-12-31 | $0.17B | $1.03B | 16.15% |
| 2024-09-30 | $0.16B | $1.08B | 15.04% |
| 2024-06-30 | $0.14B | $1.11B | 12.30% |
| 2024-03-31 | $0.11B | $1.09B | 10.22% |
| 2023-12-31 | $0.12B | $1.05B | 10.95% |
| 2023-09-30 | $0.10B | $1.02B | 9.88% |
| 2023-06-30 | $0.37B | $1.03B | 36.28% |
| 2023-03-31 | $0.43B | $1.03B | 41.46% |
| 2022-12-31 | $0.47B | $1.03B | 46.26% |
| 2022-09-30 | $0.56B | $1.00B | 55.36% |
| 2022-06-30 | $0.36B | $0.95B | 37.91% |
| 2022-03-31 | $0.38B | $0.90B | 41.85% |
| 2021-12-31 | $0.38B | $0.92B | 40.95% |
| 2021-09-30 | $0.36B | $0.94B | 38.02% |
| 2021-06-30 | $0.35B | $0.95B | 36.52% |
| 2021-03-31 | $0.32B | $0.97B | 33.50% |
| 2020-12-31 | $0.32B | $0.89B | 35.97% |
| 2020-09-30 | $0.31B | $0.82B | 37.62% |
| 2020-06-30 | $0.29B | $0.76B | 37.64% |
| 2020-03-31 | $0.27B | $0.70B | 38.59% |
| 2019-12-31 | $0.25B | $0.65B | 37.87% |
| 2019-09-30 | $0.25B | $0.61B | 41.12% |
| 2019-06-30 | $0.25B | $0.51B | 48.60% |
| 2019-03-31 | $0.25B | $0.43B | 57.77% |
| 2018-12-31 | $0.24B | $0.36B | 67.42% |
| 2018-09-30 | $0.23B | $0.30B | 75.50% |
| 2018-06-30 | $0.21B | $0.32B | 65.12% |
| 2018-03-31 | $0.20B | $0.33B | 59.95% |
| 2017-12-31 | $0.18B | $0.35B | 52.40% |
| 2017-09-30 | $0.16B | $0.36B | 43.66% |
| 2017-06-30 | $0.14B | $0.35B | 40.37% |
| 2017-03-31 | $0.12B | $0.36B | 33.75% |
| 2016-12-31 | $0.11B | $0.36B | 30.58% |
| 2016-09-30 | $0.09B | $0.37B | 24.15% |
| 2016-06-30 | $0.07B | $0.39B | 17.89% |
| 2016-03-31 | $0.05B | $0.41B | 11.79% |
| 2015-12-31 | $0.03B | $0.43B | 7.18% |
| 2015-09-30 | $0.01B | $0.46B | 3.05% |
| 2015-06-30 | $0.00B | $0.48B | -0.83% |
| 2015-03-31 | $-0.02B | $0.51B | -3.73% |
| 2014-12-31 | $-0.04B | $0.53B | -6.62% |
| 2014-09-30 | $-0.02B | $0.55B | -2.91% |
| 2014-06-30 | $-0.01B | $0.58B | -2.43% |
| 2014-03-31 | $-0.01B | $0.58B | -1.91% |
| 2013-12-31 | $-0.03B | $0.58B | -5.04% |
| 2013-09-30 | $-0.08B | $0.51B | -15.26% |
| 2013-06-30 | $-0.10B | $0.44B | -23.25% |
| 2013-03-31 | $-0.13B | $0.40B | -33.25% |
| 2012-12-31 | $-0.01B | $0.30B | -4.28% |
| 2012-09-30 | $-0.02B | $0.24B | -7.82% |
| 2012-06-30 | $-0.02B | $0.19B | -8.12% |
| 2012-03-31 | $0.00B | $0.13B | -2.34% |
| 2011-12-31 | $-0.11B | $0.12B | -92.05% |
| 2011-09-30 | $-0.09B | $0.14B | -67.77% |
| 2011-06-30 | $-0.08B | $0.12B | -72.02% |
| 2011-03-31 | $-0.08B | $0.09B | -83.65% |
| 2010-12-31 | $-0.08B | $0.07B | -108.33% |
| 2010-09-30 | $-0.08B | $0.03B | -265.57% |
| 2010-06-30 | $-0.08B | $0.02B | -368.54% |
| 2010-03-31 | $-0.08B | $0.01B | -610.91% |
| 2009-12-31 | $-0.08B | $0.01B | -1350.00% |
| 2009-09-30 | $-0.08B | $0.02B | -384.62% |
| 2009-06-30 | $-0.08B | $0.03B | -234.38% |
| 2009-03-31 | $-0.08B | $0.04B | -184.09% |
| 2008-12-31 | $-0.09B | $0.06B | -162.45% |
| 2008-09-30 | $-0.11B | $0.03B | -358.40% |
| 2008-06-30 | $-0.13B | $0.01B | -1362.16% |
| 2008-03-31 | $-0.15B | $-0.01B | 1507.69% |
| 2007-12-31 | $-0.17B | $-0.03B | 676.00% |
| 2007-09-30 | $-0.18B | $0.01B | -2346.67% |
| 2007-06-30 | $-0.18B | $0.04B | -441.21% |
| 2007-03-31 | $-0.18B | $0.08B | -233.99% |
| 2006-12-31 | $-0.18B | $0.11B | -161.63% |
| 2006-09-30 | $-0.18B | $0.11B | -165.83% |
| 2006-06-30 | $-0.18B | $0.11B | -162.53% |
| 2006-03-31 | $-0.17B | $0.11B | -148.67% |
| 2005-12-31 | $-0.15B | $0.11B | -130.42% |
| 2005-09-30 | $-0.14B | $0.15B | -92.36% |
| 2005-06-30 | $-0.12B | $0.15B | -80.00% |
| 2005-03-31 | $-0.12B | $0.12B | -101.51% |
| 2004-12-31 | $-0.11B | $0.08B | -140.40% |
| 2004-09-30 | $-0.09B | $0.03B | -334.55% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.760B | $0.411B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |